Research Library

Stem cells have two unique properties that make them an appealing therapeutic tool for regenerative medicine: they can grow indefinitely and can differentiate into a wide variety of cell types, including those that form blood, bones, lungs, skin, and the brain.

As the pandemic persisted across the state, did Texans living in cities have better access to Covid-19 vaccines than those in rural areas? How did race or age factor in? The authors assess the successes and shortfalls of Texas' vaccine distribution strategy, and how to do better next time.

By Michael W. Deem, Melia E. Bonomo and Kirstin R.W. Matthews Due to the rapidly mutating influenza virus, a new vaccine is usually developed for each flu season. In this policy brief, the authors discuss the current method used by the Centers for Disease Control and Prevention to develop the flu vaccine and propose the use of mathematical modeling to improve the vaccine's effectiveness.

Science, technology, and innovation are vital to America’s economy and workforce, and the competitiveness of U.S. industry. The authors offer five recommendations to ensure the establishment of an effective White House Office of Science and Technology Policy.

This issue brief argues that continued investments in global health and the study of emerging pathogens could yield better tools to fight infectious diseases like the Zika virus long before they become a problem in the developed world.

This policy brief urges collaboration between the United States and Mexico to address widespread epidemics of mosquito-transmitted diseases like West Nile, dengue and chikungunya in both countries. Such policy development should focus on vector control programs, public awareness and the development of vaccines to curb the spread of these diseases.

Officials in the U.S. and Mexico should coordinate a response to the spread of Chagas disease in their countries. Chagas is the third most common parasitic infection in the world.

The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.